Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance

References

• Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Med J-Peking. 2021;134(7):783–791.
   PubMed Web of Science ®Google Scholar
• Lu S, Dong X, Jian H, et al. AENEAS: a Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022;40(27):3162–3171.
   PubMedGoogle Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. New Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Reita D, Pabst L, Pencreach E, et al. Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring. Cancers (Basel). 2021;13(19):4926.
   PubMed Web of Science ®Google Scholar
• Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990–998.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y, Ahn M, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Passiglia F, Reale ML, Cetoretta V, et al. Immune-checkpoint inhibitors combinations in metastatic NSCLC: new options on the horizon? Immunotargets Ther. 2021;10:9–26.
   PubMed Web of Science ®Google Scholar
• Qiao M, Jiang T, Liu X, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn? J Thorac Oncol. 2021;16(8):1267–1288.
   PubMed Web of Science ®Google Scholar
• Chalmers AW, Patel S, Boucher K, et al. Phase I trial of targeted EGFR or ALK therapy with ipilimumab in metastatic NSCLC with long-term follow-up. Target Oncol. 2019;14(4):417–421.
   PubMed Web of Science ®Google Scholar
• Tsuchiya-Kawano Y, Shiraishi Y, Kiyomi F, et al. Phase II study of nivolumab plus ipilimumab with platinum-based chemotherapy for treatment-naive advanced non-small cell lung cancer with untreated brain metastases: nike trial (LOGiK2004). Cancer Manag Res. 2021;13:8489–8493.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in checkmate 227. J Clin Oncol. 2022.
   Google Scholar
• Boyer M, Sendur M, Rodriguez-Abreu D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >/= 50%: randomized, double-blind phase III KEYNOTE-598 Study. J Clin Oncol. 2021;39(21):2327–2338.
   PubMed Web of Science ®Google Scholar
• Gubens MA, Sequist LV, Stevenson JP, et al. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 2019;130:59–66.
   PubMed Web of Science ®Google Scholar
• Lv B, Wang Y, Ma D, et al. Immunotherapy: reshape the tumor immune microenvironment. Front Immunol. 2022;13:844142.
   PubMedGoogle Scholar
• Wang Y, Chen R, Wa Y, et al. Tumor immune microenvironment and immunotherapy in brain metastasis from non-small cell lung cancer. Front Immunol. 2022;13:829451.
   PubMedGoogle Scholar
• Su D, Wu G, Xiong R, et al. Tumor immune microenvironment characteristics and their prognostic value in non-small-cell lung cancer. Front Oncol. 2021;11:634059.
   PubMedGoogle Scholar
• Yang L, He Y, Dong S, et al. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. J Immunother Cancer. 2022;10(2):e003534.
   PubMed Web of Science ®Google Scholar
• Alwithenani A, Bethune D, Castonguay M, et al. Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR. PLoS One. 2021;16(5):e251080.
   Web of Science ®Google Scholar
• Ma T, Jiao J, Huo R, et al. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. Front Oncol. 2022;12:922899.
   PubMed Web of Science ®Google Scholar
• Luo JW, Guo YH, Wu FY, et al. Differences in immunological landscape between EGFR-mutated and wild-type lung adenocarcinoma. Dis Markers. 2021;(2021:3776854.
   PubMed Web of Science ®Google Scholar
• Taube JM, Galon J, Sholl LM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathol. 2018;31(2):214–234.
   PubMed Web of Science ®Google Scholar
• Sugiyama E, Togashi Y, Takeuchi Y, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer. Sci Immunol. 2020;5(43):43.
   Web of Science ®Google Scholar
• Isomoto K, Haratani K, Hayashi H, et al., Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 2020;26(8):2037–2046.
   PubMed Web of Science ®Google Scholar
• Selenz C, Compes A, Nill M, et al. EGFR inhibition strongly modulates the tumour immune microenvironment in EGFR-driven non-small-cell lung cancer. Cancers (Basel). 2022;14(16):3943.
   PubMed Web of Science ®Google Scholar
• Suda K, Rozeboom L, Furugaki K, et al. Increased EGFR phosphorylation correlates with higher programmed death ligand-1 expression: analysis of TKI-resistant lung cancer cell lines. Biomed Res Int. 2017;7694202:2017.
   Google Scholar
• Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18(1):165.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang H. Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors. Lung Cancer. 2021;154:221–223.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang C, Li S, et al. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Transl Lung Cancer R. 2021;10(9):3823–3839.
   PubMed Web of Science ®Google Scholar
• Jia Y, Li X, Jiang T, et al. EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies. Int J Cancer. 2019;145(5):1432–1444.
   PubMed Web of Science ®Google Scholar
• Tang J, Liu X, Gong Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC). J Clin Oncol. 2018;36(15_suppl):e21154–e21154.
   Web of Science ®Google Scholar
• Zhou J, Yu X, Hou L, et al. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer. Lung Cancer. 2021;153:143–149.
   PubMed Web of Science ®Google Scholar
• Reuben A, Zhang J, Chiou SH, et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020;11(1):603.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846.
   PubMed Web of Science ®Google Scholar
• Guaitoli G, Tiseo M, Di Maio M, et al. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer R. 2021;10(6):2890–2916.
   PubMed Web of Science ®Google Scholar
• Lee CK, Man J, Lord S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. Jama Oncol. 2018;4(2):210–216.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521–536.
   PubMed Web of Science ®Google Scholar
• Peng J, Zhao X, Zhao K, et al. Case report: long progression-free survival of immunotherapy for lung adenocarcinoma with epidermal growth factor receptor mutation. Front Oncol. 2021;11:731429.
   PubMed Web of Science ®Google Scholar
• Gianni C, Bronte G, Delmonte A, et al. Case report: Stevens-Johnson syndrome and hepatotoxicity induced by osimertinib sequential to pembrolizumab in a patient with EGFR-mutated lung adenocarcinoma. Front Pharmacol. 2021;12:672233.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Sugawara S, Fukuda Y, et al. A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L). Clin Cancer Res. 2022;28(5):893–902.
   PubMed Web of Science ®Google Scholar
• Lau S, Fares AF, Le LW, et al. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. Clin Lung Cancer. 2021;22(4):253–259.
   PubMed Web of Science ®Google Scholar
• Hastings K, Yu HA, Wei W, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019;30(8):1311–1320.
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017;28(7):1532–1539.
   PubMed Web of Science ®Google Scholar
• Miyawaki E, Murakami H, Mori K, et al. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. Jpn J Clin Oncol. 2020;50(5):617–622.
   PubMed Web of Science ®Google Scholar
• Ichihara E, Harada D, Inoue K, et al. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunol Immun. 2021;70(1):101–106.
   PubMed Web of Science ®Google Scholar
• Pasello G, Pavan A, Attili I, et al. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): increasing evidence and future applications in lung cancer. Cancer Treat Rev. 2020;87:102031.
   PubMed Web of Science ®Google Scholar
• Chiang AC, Fernandes AW, Pavilack M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Bmc Cancer. 2020;20(1):356.
   PubMed Web of Science ®Google Scholar
• Yu X, Li J, Ye L, et al. Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy. Transl Lung Cancer R. 2021;10(9):3782–3792.
   PubMed Web of Science ®Google Scholar
• Tian T, Yu M, Li J, et al. Front-line ICI-based combination therapy post-TKI resistance may improve survival in NSCLC patients with EGFR mutation. Front Oncol. 2021;11:739090.
   PubMedGoogle Scholar
• Yang L, Hao X, Hu X, et al. Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. Thorac Cancer. 2020;11(12):3501–3509.
   PubMed Web of Science ®Google Scholar
• Jiang T, Wang P, Zhang J, et al. Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. Signal Transduction Tar. 2021;6(1):355.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Diziubek K, Nagasaka M, et al. Pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-positive Non-small cell lung cancer (NSCLC). World Conference on Lung Cancer Abstracts (2021), S863 (2021).
   Google Scholar
• BH H. Tislelizumab combined with chemotherapy with or without bevacizumab in TKI-resistant EGFR-mutated non-squamous NSCLC. 2021 ESMO-IO. 2021;148.
   Google Scholar
• Choi SH, Yoo SS, Lee SY, et al. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Arch Pharm Res. 2022;45(4):263–279.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang T, Zhang L, et al. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8(+) T cells in lung cancer. Immunotherapy-Uk. 2022;14(9):695–708.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang Z, Wang Y, et al. Pembrolizumab plus chemotherapy or anlotinib vs pembrolizumab alone in patients with previously treated egfr-mutant NSCLC. Front Oncol. 2021;11:671228.
   PubMed Web of Science ®Google Scholar
• Wang P, Fang X, Yin T, et al. Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front Oncol. 2021;11:628124.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507–516.
   PubMed Web of Science ®Google Scholar
• Yang JC, Shepherd FA, Kim DW, et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thorac Oncol. 2019;14(5):933–939.
   PubMed Web of Science ®Google Scholar
• Kotake M, Murakami H, Kenmotsu H, et al. High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. Ann Oncol. 2017;28(3):669–670.
   PubMed Web of Science ®Google Scholar
• Chan DW, Choi HC, Lee VH. Superior efficacy of Combinationimmunotherapy-based combinations over monotherapy for EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced-mutant non-small cell lung cancer : A Systematic Review and Meta-Analysis acquired resistance to EGFR-TKIs. Cancers (Basel). 2022;14(9):2157.
   PubMedGoogle Scholar
• Zhao Y, Guo S, Deng J, et al. VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int J Biol Sci. 2022;18(9):3845–3858.
   PubMed Web of Science ®Google Scholar
• Ren S, Xiong X, You H, et al. The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer. Front Immunol. 2021;12:689132.
   PubMed Web of Science ®Google Scholar
• Nogami N, Barlesi F, Socinski MA, et al., IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022;17(2):309–323.
   PubMed Web of Science ®Google Scholar
• Lam TC, Tsang KC, Choi HC, et al. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. Lung Cancer. 2021;159:18–26.
   PubMed Web of Science ®Google Scholar
• Lu S, Wu L, Jian HORIENT-31. Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy. Ann Oncol. 2021;19:10–1016.
   Google Scholar
• Ma L, Qin N, Zhang X, et al. [Analysis of the efficacy of immunotherapy on the posterior lines of advanced EGFR mutant patients with non-small cell lung cancer]. Chinese J Lung Cancer. 2021;24(5):338–344.
   Google Scholar
• Hu J, Huang D, Wang Y, et al. The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: real-World evidence from a multicenter retrospective study. Front Immunol. 2022;13:975246.
   PubMedGoogle Scholar
• Liu S, Qin T, Liu Z, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309.
   PubMed Web of Science ®Google Scholar
• Fan P, Qiang H, Liu Z, et al. Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front Immunol. 2022;13:937924.
   PubMed Web of Science ®Google Scholar